Cite
HARVARD Citation
Johnsson, M. et al. (2022). No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab. Multiple sclerosis. pp. 2070-2080. [Online].